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Abstract: Silymarin is a hepatoprotective mixture of flavonolignans and flavonoids extracted from the
seeds of milk thistle (Silybum marianum L. Gaertn). This study investigates the effect of major bioactive
constituents from silymarin, silybin A, silybin B, isosilybin A, isosilybin B, silydianin, silychristin,
isosilychristin, and taxifolin, on the expression of ABCA1, an important cholesterol efflux transporter,
in THP-1-derived macrophages. Four of the studied compounds, isosilybin A, silybin B, silychristin
and isosilychristin, were found to significantly induce ABCA1 protein expression without affecting
cell viability. Moreover, isosilybin A, a partial PPARγ agonist, was found to promote cholesterol
efflux from THP-1 macrophages in a concentration-dependent manner. These findings first show
ABCA1 protein up-regulating activity of active constituents of silymarin and provide new avenues
for their further study in the context of cardiovascular disease.
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1. Introduction
Natural products have proven their potential as a source for development of very successful
therapeutics [1]. Silymarin is the main bioactive component extracted from the seeds of milk thistle,
Silybum marianum (L.) Gaertn. (Asteraceae), which is used as a hepatoprotective agent. Silymarin
is a standardized mixture of flavonolignans, and mainly composed of silybin (synonymous with
silibinin), isosilybin, silydianin and silychristin, and small amounts of other phenolic compounds,
such as quercetin, dehydrosilybin, isosilychristin and taxifolin [2–4]. Silybin is a mixture of silybin
A and silybin B, while isosilybin is a mixture of isosilybin A and isosilybin B [5]. The main use of
silymarin is focused on its hepatoprotective properties. A meta-analysis of five trials with in total
602 patients with (alcoholic) liver cirrhosis found that silymarin significantly reduced liver-related
mortality by around 7% compared with placebo treatment [6]. Besides, silymarin was proposed as
a potential hypocholesterolaemic agent protecting fatty liver development caused by disordered
lipid metabolism [7]. Furthermore, silymarin significantly improved plasma lipoprotein profile, e.g.,
by increasing the levels of high density lipoprotein (HDL) and decreasing the levels of VLDL and
triacylglycerol (TAG) in rats fed cholesterol-rich diet. Moreover, silymarin positively influences liver
lipid content, inhibits cholesterol absorption and thereby counteracts the development of fatty liver,
rationalizing its use to combat hypercholesterolemia overall [8–10]. Although silymarin is generally
prescribed as a hepatoprotective agent in a range of different conditions, it should be noted that its
efficacy in some liver-related disorders is still debated. A recent randomized controlled trial failed
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to demonstrate effectiveness of silymarin supplementation on liver disease in patients with chronic
hepatitis C unsuccessfully treated with interferon therapy [11].
The transmembrane ATP-binding cassette transporter A1 (ABCA1) protein plays a crucial role
in reverse cholesterol transport (RCT), by transferring intracellular cholesterol and phospholipids
to lipid-poor apolipoproteins. The efflux of cholesterol from macrophages or tissues by ABCA1 is
considered beneficial in the prevention of cardiovascular disease [12]. Loss of ABCA1 protein occurs in
serious inherited diseases, such as Tangier disease and familial HDL deficiency, which are accompanied
by decreased cholesterol efflux and atherosclerosis development [13]. A clinical study found that
ABCA1 mutations are associated with increased intima-media thickness resulting from decreased
cholesterol efflux [14]. Cholesterol efflux is the first step of RCT, and it comprises transmembrane
transporter-mediated transfer of intracellular cholesterol to extracellular lipid-poor lipoproteins. There
are three kinds of transmembrane transporter proteins with important cholesterol efflux-mediating
functions, particularly ABCA1, ABCG1, and scavenger receptor class B member 1 (SR-B1). Among
them, the ABCA1 transporter protein is the most important one for cholesterol transportation [15].
ABCA1 expression and subsequent cholesterol efflux are known to be enhanced by activation of the
nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ) [16]. Moreover, our
previous study suggested that among the active components of silymarin, isosilybin A could partially
activate PPARγ [17]. Since silymarin exhibits beneficial effect on plasma cholesterol and lipoprotein
levels, we hypothesized that silymarin constituents might exert a direct effect on ABCA1 expression
levels. Based on this hypothesis, in this study we first investigated the ability of isosilybin A to activate
cholesterol efflux and ABCA1 expression. Furthermore, we surveyed the ABCA1-inducing activity of
further 8 key silymarin constituents (silybin A, silybin B, isosilybin B, silybin, silydianin, silychristin,
isosilychristin and taxifolin) which are unable to activate PPARγ [18].
2. Results and Discussion
2.1. Impact of the Studied Components of Silymarin on THP-1 Cell Viability
The resazurin conversion assay is a simple and versatile method of measuring mammalian
cell viability that correlates with the conversion of the nonfluorescent resazurin to highly fluorescent
resorufin [19,20]. To exclude that the nine studied silymarin constituents (silybin A, silybin B, isosilybin
A, isosilybin B, silybin, silydianin, silychristin, isosilychristin and taxifolin) (Figure 1) affect the viability
of the used THP-1 cells, we have first measured their ability to affect resazurin conversion. Digitonin,
a natural cytotoxic product, was used as positive control in this experiment. As presented in Figure 2,
none of the compounds exhibited any effect on the viability of THP-1 macrophages in the tested
concentration range (from 5 to 30 µM), whereby digitonin, tested at 40.7 µM (equaling 50 µg/mL),
decreased THP-1 cell viability by around 90%.
2.2. Impact of Isosilybin A on Cholesterol Efflux
Knowing isosilybin A as a partial PPARγ agonist [17] and PPARγ as activator of
macrophage cholesterol efflux, we were prompted to survey cholesterol efflux in human
THP-1-derived macrophages after treatment with isosilybin A. As shown in Figure 3, isosilybin
A concentration-dependently induced cholesterol efflux from 1 to 30 µM (EC50 = 4.1 µM), mimicking
the effect of pioglitazone (10 µM), a well-established PPARγ agonist, that was used as a positive
control [21].
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Figure 1. Silymarin constituents investigated in this study.
Figure 2. Effect of the investigated compounds on THP-1 cell viability. Resazurin conversion assay was
used for the analysis of THP-1 viability. THP-1 cells were first differentiated into macrophages with
200 nM PMA for 72 h. Then, cells were treated with solvent vehicle control (DMSO), 50 µg/mL digitonin
and the indicated compounds from 5 to 30 µM for 24 h. After the treatment, THP-1 macrophages were
washed and incubated with 10 µg/mL resazurin for another 4 h. Fluorescence of converted resorufin
was measured and the increased fluorescent signal was quantified as cell viability. Experiments were
performed three times in triplicate. All values are mean ˘ SD (n = 3) compared to the solvent vehicle
control (DMSO), n.s.: not significant, *** p < 0.001 (ANOVA/Bonferroni).
Molecules 2016, 21, 55 4 of 8
Figure 3. Effect of isosilybin A, a partial PPARγ agonist, on apo A1-mediated cholesterol efflux. First,
THP-1 monocytes were differentiated into adherent macrophages by treatment with 200 nM PMA for
72 h. The differentiated THP-1 macrophages were loaded with [3H]-cholesterol together with solvent
vehicle control (DMSO), pioglitazone (10 µM) and varying concentrations of isosilybin A (from 1 to
30 µM) in serum-free medium with 0.1% fatty acid free BSA and 10 µg/mL unesterified cholesterol for
24 h to achieve equilibration of the intracellular cholesterol pool. After that, cells were incubated with
the same treatments with or without 10 µg/mL apo A1 dissolved in serum-free medium for 6 h. The
[3H]-cholesterol released into the medium as well remaining in the cell lysates was quantified by liquid
scintillation counting. Three independent experiments were performed. All values are mean ˘ SD
(n = 3) compared to the solvent vehicle control (DMSO), n.s.: not significant, ** p < 0.01, *** p < 0.001
(ANOVA/Bonferroni).
2.3. Impact of the Active Components of Silymarin on ABCA1 Protein Expression
PPARγ agonists increase cholesterol efflux through up-regulation of ABCA1 protein levels [16,21].
Therefore, we next investigated whether isosilybin A leads to ABCA1 up-regulation. Next to isosilybin
A, we also evaluated eight other silymarin constituents (at 10 µM), which are not PPARγ agonist [18].
Figure 4 presents the results obtained upon quantification of the ABCA1 protein expression levels. As
expected, isosilybin A (10 µM) induced a significant up-regulation of the ABCA1 protein expression,
showing a 1.25-fold activation compared to the solvent vehicle control (DMSO, 0.1%) treated cells.
Interestingly, besides isosilybin A, four of the other investigated compounds, silybin B, silychristin,
isosilychristin, and taxifolin, also induced ABCA1 expression.
Notably, some of the tested structurally similar compounds exhibit a quite distinct
ABCA1-inducing potential. For example, silybin B significantly induced ABCA1 protein expression
with a 1.42-fold activation, whereas silybin A exerted no effect. As a mixture of silybin A and silybin B,
silybin showed slight up-regulation of ABCA1 protein level with a 1.22-fold activation. Therefore, the
difference in stereochemistry appears crucial for the ABCA1-inducing activity. However, unlike the pair
of silybin A and silybin B, silychristin and isosilychristin showed almost the same effect, upregulating
ABCA1 1.36- and 1.40-fold, respectively. In this case, the stereochemical difference between silychristin
and isosilychristin seems not crucial for the ABCA1 protein up-regulation in THP-1 macrophages.
Taxifolin (dihydroquercetin) is a flavonoid with simpler chemical structure compared with the other
active components of silymarin. Though its effect is not strong (1.15-fold activation), it significantly
increased the ABCA1 protein expression in THP-1 macrophages. In our previous study, taxifolin even
decreased PPARγ activity [17], indicating overall the existence of alternative (different than PPARγ
activation) ABCA1 expression-enhancing mechanisms affected by the silymarin constituents in our
cell model.
PPARγ activation is a very well established enhancer of ABCA1 expression leading to increased
macrophage cholesterol efflux. The enhanced efflux might therefore be due to PPARγ-activation upon
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isosilybin A treatment, although the existence of additional molecular mechanisms of action cannot be
ruled out. Moreover, a causal link between increased ABCA1 level and increased efflux is not directly
demonstrated in our work. Furthermore, since silybin B, silychristin, isosilychristin, and taxifolin
are not active or even inhibit PPARγ, their ABCA1-enhancing effects are likely mediated through
mechanisms other than PPARγ activation.
Figure 4. Effect of the investigated compounds on ABCA1 protein levels. Western blot analysis shows
ABCA1 protein expression levels. THP-1 macrophages were treated with solvent control (DMSO) or
the investigated compounds (10 µM). After 24 h incubation, cells were lysed and proteins analyzed via
SDS-PAGE. (A) presents the compounds silybin A, isosilychristin, silybin B and silychristin; (B) presents
the compounds isosilybin B, taxifolin, silybin and silydianin. Experiments are independently performed
three times, and representative images are shown; The summarized results from the quantification of
all performed experiments are presented in (C). All values are mean (n = 3) compared to the solvent
vehicle control (DMSO), two-tailed t-test was used for statistics.
3. Materials and Methods
3.1. Chemicals, Cell Culture Reagents and Antibodies
Pioglitazone was bought from Molekula (Munich, Germany) and [3H]-cholesterol (1 mCi, 37 MBq)
from Perkin Elmer Life Sciences (Vienna, Austria). Digitonin was purchased from Sigma-Aldrich via
Fluka (Vienna, Austria). Bovine serum albumin (BSA) was obtained from Roth (Karlsruhe, Germany).
Resazurin sodium salt, water soluble unesterified cholesterol, apolipoprotein (apo) A1, and phorbol
12-myristate 13-acetate (PMA) were provided by Sigma-Aldrich.
Phenol red Roswell Park Memorial Institute (RPMI) 1640 medium without L-glutamine was
purchased from Lonza (Basel, Switzerland). Fetal bovine serum (FBS) was from Gibco (Lofer, Austria).
Primary antibody against ABCA1 was provided by Novus Biologicals (Vienna, Austria). The
anti-actin antibody was obtained from MP biologicals (Illkirch, France). HRP-linked anti-rabbit IgG
secondary antibody was acquired from New England Biolabs (Frankfurt, Germany) and horseradish
peroxidase conjugated goat anti-mouse secondary antibody from Upstate (Millipore, Vienna, Austria).
All antibodies were diluted 1:500 except the anti-mouse secondary antibody (1:10,000).
Molecules 2016, 21, 55 6 of 8
3.2. Sources of the Compounds
The sources of the compounds were described in detail previously [17]. Isosilybin A and its
derivatives were dissolved in dimethyl sulfoxide (DMSO) at 30 mM, aliquoted and stored at ´20 ˝C
until use. An equal amount of DMSO was used for each condition in all experiments and the final
DMSO concentrations did not exceed 0.1% to assure that the solvent vehicle does not influence the
results itself.
3.3. Cell Culture
The human THP-1 monocytic cells were obtained from ATCC® and grown in RPMI-1640 medium
supplemented with 2 mM glutamine, 100 U/mL benzylpenicillin, 100 µg/mL streptomycin and 10%
heat-inactivated FBS,. The THP-1 cells were cultured in T175 flasks at 5% CO2 and 37 ˝C, and split
every two days to assure that the concentration is not exceeding 0.8 ˆ 106 per mL (to assure cell
viability > 95%).
3.4. Resazurin Conversion Assay
The assay was performed as previously described with slight modifications [20]. THP-1 cells
were seeded in 96-well plates at a density of 0.2 ˆ 106 per mL in a volume of 100 µL per well.
THP-1 macrophages were acquired by treatment with 200 nM PMA for 72 h in RPMI-1640 medium
supplemented with 10% heat-inactivated FBS. After differentiation, THP-1 macrophages were washed
once with warm PBS (37 ˝C) and treated with the indicated compounds at 5, 10, 20 and 30 µM in
RPMI-1640 FBS-free medium supplemented with 0.1% BSA and 10 µg/mL unesterified cholesterol.
The saponine digitonin, was used as positive control (50 µg/mL). After 24 h incubation with the
compounds, cells were washed once with warmed PBS again and incubated with 10 µg/mL resazurin
which is dissolved in PBS to allow the conversion to the highly fluorescent resorufin. After 4 h
incubation, the plates were read with a Tecan GENiosPro plate reader (Männedorf, Switzerland) at a
wavelength of 580 nm (emission) and 535 nm (excitation).
3.5. ABCA1 Protein Quantification
Western blot analysis was used for relative ABCA1 protein quantification. Briefly, cells were
seeded in 6-well plates at a density of 0.2 ˆ 106 per mL with a volume of 4 mL for each well. THP-1
monocytes were differentiated into macrophages in RPMI-1640 medium supplemented with 10%
heat-inactivated FBS in the presence of 200 nM PMA for 72 h. After differentiation, cells were washed
once with pre-warmed PBS and loaded with the indicated compounds at 10 µM. Cells were incubated
with the respective compounds for 24 h, a period of time that appeared in pilot experiments as optimal
for ABCA1 induction by PPARγ agonists such as pioglitazone. Cells were then washed once with
cold PBS and then lysed with NP40 buffer (150 mM NaCl; 50 mM HEPES (pH 7.4); 1% NP40; 1%
protease inhibitor Complete™ (Roche); 1% phenylmethylsulfonyl fluoride (PMSF); 0.5% Na3VO4;
0.5% NaF) for 30 min at 4 ˝C. The lysed cells were collected with a scratcher and centrifuged for
20 min at 16,060 g. Cell pellets were discarded and the supernatant was transferred into a new
Eppendorf tube for total protein quantification using a Bradford assay. Twenty micrograms of protein
was resolved via 10% SDS polyacrylamide gel electrophoresis (SDS-PAGE) for 80 min at 25 mA
per gel for separation. The fractionated protein was analyzed with antibodies against ABCA1 and
actin, respectively. Protein bands were visualized with ECL reagent and a LAS-3000 luminescent
image analyzer (Fujifilm, Düsseldorf, Germany) using AIDA image analyzer 4.06 software (Raytest,
Sprockhövel, Germany).
3.6. Cholesterol Efflux Assay
Human THP-1 monocytic cells were seeded in 24-well plates at a density of 0.2 ˆ 106 per mL with
a volume of 1 mL for each well. Cells were differentiated into adherent macrophages with 200 nM PMA
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for 72 h in RPMI-1640 medium containing 10% FBS. THP-1 cells were washed once with pre-warmed
PBS and loaded with 0.3 µCi/mL [3H]-cholesterol together with 10 µM pioglitazone or varying
concentrations of isosilybin A in serum-free RPMI-1640 medium containing 0.1% BSA and 10 µg/mL
unesterified cholesterol. After equilibrating the cholesterol pools for 24 h, THP-1 macrophages were
washed twice with warmed PBS and incubated in serum-free RPMI-1640 medium with the same
compounds (pioglitazone or isosilybin A) in the presence and absence of apo A1 (10 µg/mL) for 6 h.
The [3H]-cholesterol released into the medium (extracellular radioactivity) and maintained in the cell
lysates (intracellular radioactivity) were quantified by liquid scintillation counting. The assays were
performed in triplicate and the percent apo A1-mediated cholesterol efflux was calculated as follows:
Apo A1 mediated cholesterol efflux = [((extracellular cpm) apo A1/(intracellular cpm +
extracellular cpm) apo A1) ˆ 100] ´ [((extracellular cpm) no apo A1/(intracellular cpm + extracellular
cpm) no apo A1) ˆ 100].
3.7. Statistical Analysis
All experiments in this study were performed at least three times independently. Figures with bar
graphs are presented as mean ˘ SD. One-way analysis of variance (ANOVA) and t-tests were used
for statistical analysis using GraphPad Prism software version 4.03 (GraphPad Software Inc., La Jolla,
CA, USA). The differences were considered significant when p < 0.05, indicated with one asterisk (*).
Further details for each experiment can be found in the respective figure legends.
4. Conclusions
In summary, we identify the silymarin constituents isosilybin A, silybin B, silychristin,
isosilychristin, and taxifolin to increase ABCA1 expression in THP-1-derived macrophages. In
addition, isosilybin A promotes cholesterol efflux from macrophages in a concentration-dependent
manner, possibly due to its PPARγ-activating properties. Overall, our study provides for the first time
evidence for ABCA1-upregulating effects of silymarin constituents, providing a possible link to its
described hypocholesterolaemic in vivo action, and opening new research directions that might help to
better understand molecular mechanisms underlying the action of this important health-promoting
herbal product.
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